Acrivon Therapeutics (ACRV) announced it will present data from AP3 Generative Phosphoproteomic analyses of ACR-2316-regulated CDK1-, CDK2-, ...

WEE1 acts as a master regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. By inhibiting WEE1 ...

WEE1 acts as a master regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. By inhibiting WEE1 ...

In the presence of a drug (MG132) that inhibits proteasome activity, cells cannot exit mitosis because cyclins cannot be degraded and Cdk1–CycB activity stays high (M phase). By applying a ...

Open label data from the study are expected in the second half of 2025. WEE1 inhibition has emerged as a promising strategy for targeting tumor cells with high replication stress and DNA damage ...

Two preclinical data releases will be included in the poster display sessions for Debio 0123, a selective WEE1 kinase inhibitor disrupting the DNA-damage response (DDR) of cancer cells.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, and SGR-4174, its SOS1 inhibitor ...

“We continue to enroll patients in the ACESOT-1051 trial evaluating our WEE1 kinase inhibitor, APR-1051, which we believe has best in class potential. The compound appears safe and well ...

The poster will include clinical data as of an April 4, 2025 data cutoff from the Company's ongoing Phase 1/2 clinical trial evaluating azenosertib in combination with encorafenib and cetuximab in ...